The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.
 
Guzman Alonso
Consulting or Advisory Role - Boehringer Ingelheim; Ellipses Pharma
 
Pilar Garrido
Employment - Teva (I)
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Daiichi Sankyo Europe GmbH; Gebro Pharma (I); IO Biotech; Janssen Oncology; MSD Oncology; Nordic Group (I); Pfizer; PharmaMar; Pierre Fabre; Regeneron; Roche Pharma AG
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; Lilly; Pfizer
Travel, Accommodations, Expenses - AstraZeneca Spain; Johnson & Johnson/Janssen; Roche Pharma AG
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Judy Wang
Consulting or Advisory Role - Fusion Pharmaceuticals
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Alterome Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Biostar (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); BMS GmbH & Co. KG (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Celgene/Bristol-Myers Squibb (Inst); Centessa Pharmaceuticals (Inst); Circle Pharma (Inst); Compass Therapeutics (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); DualityBio (Inst); Edgewood Oncology (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Genmab (Inst); Georgiamune (Inst); GlaxoSmithKline (Inst); Hotspot Therapeutics (Inst); IgM Biosciences (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Kineta (Inst); Klus Pharma (Inst); Kumquat (Inst); Kura Oncology (Inst); Kymab (Inst); Loxo/Lilly (Inst); LSK Global (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MBQ Pharma (Inst); Medikine (Inst); MediLink Therapeutics (Inst); Menarini (Inst); Merck KGaA (Inst); Mersana (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyxis (Inst); Qilu Puget Sound Biotherapeutics (Inst); Quanta Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Syndax (Inst); Tango Therapeutics (Inst); TeneoBio (Inst); Treadwell Therapeutics (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Lab (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - NGM Biopharmaceuticals
 
Andrew Gianoukakis
Consulting or Advisory Role - Eisai
Research Funding - Ellipses Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Matthew Taylor
Honoraria - Bristol Myers Squibb Foundation; Exelixis; OncoSec; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
 
Stephen Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Gilead Sciences; GlaxoSmithKline; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merus; Mirati Therapeutics; MSD Oncology; Natera; Novartis; OSE Immunotherapeutics; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Takeda; Yuhan
Research Funding - Abbvie (Inst); Alkermes (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Cogent Biosciences (Inst); Duality Biologics (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Systimmune (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Luis Paz-Ares
Leadership - ALTUM Sequencing; Stab Therapeutics
Stock and Other Ownership Interests - Altum Sequencing; Stab therapeutics
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Gilead Sciences; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Regeneron; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Pfizer; Pharmamar; Regeneron; Roche; Sanofi; Takeda
Speakers' Bureau - Amgen; AstraZeneca; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); MSD (Inst); Pfizer (Inst); PharmaMar (Inst)
Other Relationship - Amgen (I); Astellas Pharma (I); Crinetics Pharmaceuticals (I); Esteve (I); HUTCHMED (I); Ipsen (I); ITM Isotope Technologies Munich (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Martin Forster
Consulting or Advisory Role - Achillies; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; EQRx; GlaxoSmithKline; Immutep; Janssen; Merck; MSD; Oxford VacMedix; Pfizer; PharmaMar; Regeneron; Roche; Takeda; Transgene; Ultrahuman
Research Funding - AstraZeneca; Boehringer Ingelheim; Merck; MSD
Travel, Accommodations, Expenses - Achilles Therapeutics; AstraZeneca; Immutep; Janssen; MSD Oncology; Roche; Takeda
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Saad Khan
Consulting or Advisory Role - Eisai; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Kineta
Research Funding - Abbvie (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Formation Biologics (Inst); Genentech (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst)
 
Jyoti Patel
Consulting or Advisory Role - Abbvie; Anheart Therapeutics; AstraZeneca; Blueprint Medicines; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Guardant Health; Sanofi; Takeda Science Foundation
Travel, Accommodations, Expenses - Tempus
 
Salman Punekar
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); Constellation Pharmaceuticals (Inst); NCI (Inst); Neogene Therapeutics (Inst); Prelude Therapeutics (Inst); Revolution Medicines (Inst); Simcere (Inst); Tango Therapeutics (Inst); VITRAC Therapeutics (Inst)
 
Daniel Morgensztern
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bayer; Bristol-Myers Squibb/Medarex; G1 Therapeutics; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Genprex (Inst); Heat Biologics (Inst); Hybercell (Inst); ImmunityBio (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Genprex
 
Susanne Arnold
Consulting or Advisory Role - Penn State Cancer Institute
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics, Inc (Inst); Ellipses Pharma (Inst); Fortrea Inc (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Lisata Therapeutics, Inc. (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); National Cancer Institute (Inst); Ohio State University (Inst)
 
Javier García-Corbacho
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Puma Biotechnology (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - BMS; Pfizer (Inst)
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Bayer; Guardant Health; Janssen; OM Pharma; Roche; Seagen; Zai lab
Speakers' Bureau - BMS; Eisai; Guardant Health; Janssen; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio; BerGenBio; BMS; Immutep; Janssen; Roche; Roche; Zai Lab
 
Jack Welch
Employment - Theradex
Leadership - Oncorena
 
Sonia Serrano
Employment - Ellipses Pharma
 
Hendrik-Tobias Arkenau
Employment - Ellipses Pharma; Hospital Corporation of America; SArah CAnnon Research Institute UK; SArah CAnnon Research Institute UK
Honoraria - BeiGene; Guardant Health; SERVIER
Consulting or Advisory Role - Engitix; iOnctura
Research Funding - Sarah Cannon Research Institute
 
Elena Garralda
Employment - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Consulting or Advisory Role - Abbvie; Alentis Therapeutics; Amgen; Anaveon; Astex Pharmaceuticals; Boehringer Ingelheim; Daiichi Sankyo/Lilly; Ellipses Pharma; Genmab; Gilead Sciences; Greywolf; Hengrui Therapeutics; Incyte; Janssen; Marengo Therapeutics; Medpace; Medscape; Pfizer; Roche; Sanofi; Seagen; Skypta; Sotio
Speakers' Bureau - AEFI; Alcura; Aran; AstraZeneca; CDDF; Doctaforum; ESMO; Fundación ECO; Fundación SEOM; Horizon CME; Karger Publishers; Medscape; MeetingPharma; MSD; Novartis; PPD Global; Roche; Seagen; Springer Nature; Tactics; The Ricky Rubio Fundation
Research Funding - Anaveon; AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)